RNXT Research and Charts

RNXT - RenovoRx Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2024-08-16 (Delayed quote data 2025-01-06)

Last 1.37	Change ⇓ -0.01 (-0.72%)	Volume 48,821
	Open 1.41	High 1.44	Low 1.35

8EMA (Daily) 1.33	40EMA (Daily) 1.25	50EMA (Daily) 1.23	STO (Daily) 65.117	MACD Hist (Daily) 0.014
8EMA (Weekly) 1.295	40EMA (Weekly) 1.24	50EMA (Weekly) 1.27	STO (Weekly) 69.114	MACD Hist (Weekly) 0.069


Company Profile
RenovoRx Inc is a clinical-stage biopharmaceutical company. It is focused on developing therapies for the local treatment of solid tumors and conducting a Phase 3 registrational trial for lead product candidate RenovoGem.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.